The first authorisation for
innovative treatment using CAR T-cells for certain types of
cancer may soon be granted.
The new Board of Director of the Italian Medicines Agency
(AIFA) is expected to meet in the coming days and approval for
the therapy will be one of the first items on the agenda.
The agreement will involved AIFA and CAR T-cell producer
Novartis, with the Italian public healthcare service covering
the costs on the basis of the effectiveness of the therapy.
The accord would see the healthcare service reimbursing the
costs of the therapy if it were to prove effective on the
individual patients. Otherwise the company will have to pick up
the costs.
ALL RIGHTS RESERVED © Copyright ANSA
